AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00312494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Flexible dosing, 20-40mg BID, with a mood stabilizer (either lithium or divalproex)
Study NCT00312494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Flexible dosing, 60-80mg BID, with a mood stabilizer (either lithium or divalproex)
Study NCT01002755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01066624 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse
Description: Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
Study NCT00412360 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Umbilical Cord Blood Unit Transplant
Description: Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
Study NCT00412360 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Umbilical Cord Blood Unit Transplant
Description: Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
Study NCT01002755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study NCT02771990 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: sham stimulation
Study NCT02771990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: 2 milliamp (mA) 20 minutes
Study NCT00925418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frozen Glove
Description: Using frozen glove during chemotherapy with Taxotere®
Study NCT02674867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Study NCT02691299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fruquintinib
Description: Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
Study NCT03995706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: All 20 subjects will receive study drug Sacituzumab Govitecan preoperatively. Intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling. Samples will be tested for total SN-38and free SN-38, as well as SN-38G. Following recovery from surgery, patients will resume treatment
Study NCT03240159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Degarelix 24mg Degarelix 16mg Degarelix 12mg~Active Comparator:~Down regulation of LH, during exposing in three different doses of Degarelix
Study NCT03094065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin
Study NCT03094065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study NCT04772508 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Scaling and root planing
Description: 15 sites with periodontal pockets ≥ 5mm received only SRP
Study NCT04772508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: 15 sites with periodontal pockets ≥ 5mm received only SRP
Study NCT04772508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amnion membrane
Description: 15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane.
Study NCT04772508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taurine
Description: 15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane hydrated with taurine.
Study NCT04541628 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SIG-001
Description: Laparoscopic administration of SIG-001 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce BDD-hFVIII.
Study NCT00391612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exhale® Drug-Eluting Stent
Description: Bronchoscopic procedure in which up to six Exhale Drug-Eluting Stents are placed in the lungs; total procedure time is 1 to 2 hours
Study NCT00391612 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: 5-10 minute bronchoscopic procedure in which the lungs are examined and a bronchial lavage is performed; the bronchoscope is then retracted to a point above the carina and below the vocal folds for the remained of the time; total procedure time is about 1-2 hours
Study NCT03320590 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Time Lapse (material to observe embryonic development)
Description: The embryonic kinetics are recorded by Time lapse Primovision™ (Vitrolife). These kinetic parameters are analysed and annotated by only one person with expertise in this technology.
Study NCT00156390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: echo-guided left ventricular lead placement
Description: placement of the LV lead of the biventricular pacing device under echocardiographic guidance
Study NCT00156390 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LV lead placement as per standard of care (without echo guidance)
Study NCT02085278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Micro Catheter device
Description: Detachable Tip Micro catheter
Study NCT01847976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
Study NCT00412360 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
Study NCT00950742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Load: 4mg/kg-maintain:2mg/kg/week
Study NCT00412360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
Study NCT00412360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
Study NCT00412360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
Study NCT00412360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: MMF will be given at a dose of 1 gram IV q 8 hours if > 50 kg or 15 mg/kg IV q 8 hours if \< 50 kg beginning the morning of Day -3.
Study NCT03529201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLB
Description: On the side of the surgery, QLB with 0.375% ropivacaine (0.2 mL/kg)
Study NCT03529201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCA
Description: Patient-controlled analgesia
Study NCT03529201 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GA
Description: General anesthesia
Study NCT00950742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: Increased dose cohorts from low dose to MTD
Study NCT02691299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
Study NCT02652078 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal shockwave therapy
Description: Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)
Study NCT02652078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Description: Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)
Study NCT00702403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Given PO
Study NCT00702403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study NCT00702403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04272528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: uniform care
Description: The leader develops training plan and trains nurses, who provide uniform care and education to patients according to the training.
Study NCT02101489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: 20 with intraoperative Foley catheter measurement of the urethral length and 20 without
Study NCT04272528 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional care
Description: Nurses carry out the routine care procedures.
Study NCT01204476 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT01742013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCJBP Laennec Inj.
Description: Test drug
Study NCT01742013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator
Study NCT01204476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT01204476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01204476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate
Description: Given IM
Study NCT01204476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT04749953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary sinus floor augmentation
Description: The sinus membrane of the maxillary sinus is elevated to create a space for the grafting material and placement of dental implants in the posterior maxilla
Study NCT04749953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus floor augmentation
Description: The sinus membrane of the maxillary sinus is elevated to create a space for the grafting material and placement of dental implants in the posterior maxilla
Study NCT01508975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Rice, Brown Rice, Glucose
Description: white rice, brown rice, glucose
Study NCT02195141 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional fraction
Description: capecitabine 825mg/m2 p.o. twice daily Radiotherapy 50Gy/25f
Study NCT02195141 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB
Description: Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
Study NCT00773747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Four 100 mg capsules vorinostat taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
Study NCT00773747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bortezomib
Description: 1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
Study NCT00773747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
Study NCT00773747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to vorinostat
Description: Four placebo capsules taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
Study NCT03270891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PGx test
Description: A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety. The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
Study NCT03270891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PGx test
Description: A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety. The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
Study NCT02540668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally
Study NCT02540668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Administered orally
Study NCT04360876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Description: Dexamethasone intravenous 20mg daily for 5 days followed by 10mg daily for 5 days
Study NCT04360876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo delivered intravenously on the same dosing schedule as dexamethasone
Study NCT00098306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
Study NCT00098306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Therapy
Description: Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
Study NCT00098306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Therapy
Description: Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
Study NCT00098306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
Study NCT00098306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Therapy
Description: Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
Study NCT02971150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia
Study NCT04922905 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NEURO +
Description: The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)~Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed.
Study NCT04922905 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NEURO -
Description: The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)
Study NCT03134781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DoIT workout
Description: A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management. FFIT was performed 3 times/week with 48 hours recovery between sessions for 40 weeks.
Study NCT03134781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DoIT workout - Detraining
Description: A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training, performed according to a periodized model of exercise prescription for a 20-week period (3 times/week). Immediately after a 20-week detraining period (no training was performed) was followed.
Study NCT03134781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control - No training
Description: No training was performed during a 40-week period. Participation only in measurements.
Study NCT01274520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Medtronic Portable Bypass System (PBS®)
Description: Will be used for machine perfusion of liver grafts.
Study NCT04318600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human amniotic mesenchymal stem cell
Description: human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times).
Study NCT00652886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Description: Tablets, 10mg, single-dose
Study NCT00652886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxandrin
Description: tablets, 10mg, single-dose
Study NCT03897842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprieve Cardiovascular System
Description: The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
Study NCT01374178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered subcutaneously
Study NCT01374178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus
Description: Administered subcutaneously
Study NCT01349764 — intervention group
Intervention type: DRUG
Intervention: Vitamin D3
Study NCT03187808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single thoracic manipulation
Description: The subjects, who were randomly allocated to single thoracic manipulation group, will receive the single thoracic manipulation interventions directly to both sides of zygapophyseal joints of T6-T7. Each subject will be asked to lie on prone position on an experimental table. After that, the researcher will mark on both sides of zygapophyseal joints of T6-T7. Then, the subject will be instructed to take a deep inhalation and exhalation. During the exhalation, the therapist will perform the single thoracic manipulation (screw thrust technique) at zygapophyseal joints of T6-T7. If the audio pop is not heard during the first attempt, the therapist will ask the subject to reposition and repeat the technique. The procedure will be performed for maximum of 2 attempts and within 2 minutes.
Study NCT03187808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Special massage technique (RT technique)
Description: The special massage technique or RT technique is a treatment that was developed by Puntumetakul and colleagues in 2013 (copyright registration number 314783). The subjects in this group will be asked to lie on side lying position with 90 degrees of hip flexion and 90 degrees of knee flexion. The researcher will perform the RT technique by press their thumb on the treatment lines beside the posterior vertebral line from level of inferior angle of scapula to the lowest rib for 5 seconds per point and 3 sets per treatment line (Figure 8). Total time of this procedure is approximately 2 minutes.
Study NCT03094715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombectomy
Description: Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).